Genome Accessibility and Modification Group

Another group just started to work on the CABMM Research Platform: Andrew Seeber and Michael Hauer aim to improve CRISP-Cas9 efficiency for gene editing in human cells. Embedded with both the DMMD (Altmeyer Group) and the CABMM, the Genome Accessibility and Modification Group is another example of successful collaborations within our network. For more information please visit the CABMM Research Platform.

Marina Klawitter

News